Alla studier
AuktoriseradTerapeutisk utforskande (Fas II)Interventionell

A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects with HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)

This study is called 'FERROCLEAR' and is for adults aged 18 and over who have a specific type of hereditary hemochromatosis. This condition causes the body to absorb too much iron, which can then build up in organs like the liver. The study is testing a new medicine called Vamifeport to see how well it works at lowering these high iron levels in the liver. Researchers will also be checking if the medicine is safe. Some participants will receive Vamifeport, while others will receive a dummy pill (placebo) to fairly compare the new medicine's effects. Everyone involved, including the study doctors, won't know who is getting which.

Överblick

Status
Auktoriserad
Fas
Terapeutisk utforskande (Fas II)
Sponsor
CSL Behring LLC
Inskrivningsmål
50
Starta
20 apr 2026

Vad handlar denna studie om?

This study is looking at a new medicine called Vamifeport for adults who have a condition known as hereditary hemochromatosis, specifically the type linked to the HFE gene. If you have this condition, your body absorbs too much iron from your food. Over time, this extra iron can build up in important organs like your liver, heart, and pancreas, which can cause health problems.

The main goal of this study is to see if Vamifeport can help lower the amount of iron stored in the liver. We will measure this using a special type of MRI scan. The study will also carefully check for any side effects to make sure the medicine is safe. Everyone taking part will either receive Vamifeport or a dummy pill (called a placebo) that looks exactly like Vamifeport. Neither you nor your study doctor will know which one you are receiving – this helps us get the most accurate results.

This kind of study, called a Phase 2 trial, is an important step in developing new medicines. It helps us understand if a new treatment is effective and safe enough to move on to larger studies. Your participation could help us learn more about treating this condition in the future.

Viktiga punkter

  • This study is for adults with a specific type of hereditary hemochromatosis (HFE-related).
  • It's testing a new medicine called Vamifeport to see if it lowers iron in the liver.
  • Participation involves regular clinic visits, blood tests, and MRI scans.
  • Some participants will get the study medicine, while others will get a dummy pill (placebo).
  • You will be closely monitored for any health changes or side effects.
  • Your involvement could help advance treatment for this condition.

Vem kan vara berättigad?

To be part of this study, you must be an adult, at least 18 years old. The study is open to both men and women.

The most important thing is that you must have hereditary hemochromatosis linked to the HFE gene. This is a specific type of iron overload condition.

There might be other health requirements or specific things about your condition that the study doctors will need to check to make sure the study medicine is right and safe for you. Your doctor will be able to tell you all the details to see if you can take part.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Är du 18 år eller äldre?
  2. Do you have hereditary hemochromatosis?
  3. Has your doctor told you that your hemochromatosis is 'HFE-related'?
  4. Are you comfortable with regular clinic visits and various medical tests, including MRI scans?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you decide to join this study, you will have regular visits to the clinic. During these visits, doctors and nurses will perform various tests and checks, including blood tests and physical examinations. You will also have special MRI scans to measure the iron levels in your liver at different times throughout the study. You will be given either the study medicine, Vamifeport, or a placebo (dummy pill) to take regularly as instructed. The study team will monitor you closely to see how you are responding to the treatment and to check for any side effects. After you finish taking the study medicine, there will be follow-up appointments to ensure your health is stable. The total duration of your participation in the study will be explained in detail by the study team.

Potentiella risker och fördelar

Participating in this study might offer you access to a new potential treatment for your condition before it is widely available. You will also receive regular health check-ups and close monitoring by medical professionals. However, there are also potential risks of taking any new medicine, including unknown side effects. Your health condition may not improve, or it could even worsen. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Platser (11)

Vissa platsangivelser är ungefärliga. Vi arbetar på att förbättra detta — vänligen kontrollera med testteamet innan du reser.
  • —
    Obekräftad
    Österrike
  • —
    Obekräftad
    Polen
  • —
    Obekräftad
    Spanien
  • —
    Obekräftad
    Tyskland
  • —
    Obekräftad
    Frankrike
  • —
    Obekräftad
    Irland
  • —
    Obekräftad
    Rumänien
  • —
    Obekräftad
    Belgien
  • —
    Obekräftad
    Italien
  • —
    Obekräftad
    Tjeckien
  • —
    Obekräftad
    Nederländerna

Vanliga frågor

What is hereditary hemochromatosis?

It's a condition where your body absorbs and stores too much iron, which can build up in organs and cause problems.

Vad är en 'placebo'?

A placebo is a dummy pill that looks exactly like the study medicine but contains no active drug. It helps compare the new medicine's effects fairly.

Kommer jag att veta om jag får den riktiga medicinen eller placebo?

Neither you, nor your study doctor, will know which treatment you are receiving until after the study is over. This is called 'double-blind'.

What is an MRI scan for my liver?

It's a special scan that uses strong magnets and radio waves to create detailed pictures inside your body, including measuring iron in your liver.

Kan jag lämna studien om jag ändrar mig?

Yes, you have the right to leave the study at any time, for any reason, without it affecting your future medical care.

Hur du får reda på mer

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.